Hip viscosupplementation under ultra-sound guidance riduces NSAID consumption in symptomatic hip osteoarthritis patients in a long follow-up. Data from Italian registry

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 1, 2011, Pages 25-34

  Migliore, A ^a   Granata, M ^b   Tormenta, S ^b   Lagana B ^a   Piscitelli, P ^c   Bizzi, Emanuele ^a   Massafra, U ^a   Alimonti, A ^a   Maggi, C ^d   De Chiara, R ^e   Iannessi, F ^b   Sanfilippo, A ^f   Sotera, R ^f   Scapato, P ^g   Carducci, S ^g   Persod, P ^h   Denaro, S ⁱ   Camminiti, M ^j   Pagano, M G ^j   Bagnato, G ^k   Iolascon, G ^l   more..

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b SAN FILIPPO NERI HOSPITAL   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d Broni Stradella Hospital   (Italy)

^e UNIVERSITY MEDITERRANEA OF REGGIO CALABRIA   (Italy)

^f UNIVERSITY OF PALERMO   (Italy)

^g General Hospital   (Italy)

^h Kinesis Center   (Italy)

ⁱ Department of Anesthesiology   (Italy)

^j BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^k UNIVERSITY OF MESSINA   (Italy)

^l SECOND UNIVERSITY OF NAPLES   (Italy)

more..

Author keywords

Hip; Hyaluronic acid; Intra articular injection; NSAID; Osteoarthritis; Ultrasound

Indexed keywords

HYALUBRIX; HYALURONIC ACID; JOINTEX; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG EFFICACY; DRUG USE; FOLLOW UP; HEALTH CARE ORGANIZATION; HIP OSTEOARTHRITIS; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; TREATMENT DURATION; ULTRASOUND; VISCOSUPPLEMENTATION; CLINICAL TRIAL; ECHOGRAPHY; INTRAARTICULAR DRUG ADMINISTRATION; MIDDLE AGED; PAIN ASSESSMENT; REGISTER;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FOLLOW-UP STUDIES; HUMANS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; MIDDLE AGED; OSTEOARTHRITIS, HIP; PAIN MEASUREMENT; REGISTRIES; RETROSPECTIVE STUDIES; ULTRASONICS;

EID: 79953150195     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. HOAGLUND FT, STEINBACH LS. Primary osteoarthritis of the hip: etiology and epidemiology. J Am Acad Orthop Surg 2001; 9: 320-327.
2. ALTMAN RD, HOCHBERG MC, MOSKOWITZ RW, SCHNITZER TJ. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum 2000; 43: 1905-1919.
3. BRADLEY JD, BRANDT KD, KATZ BP, KALASINSKI LA, RYAN SL. Comparison of an anti-inflammatory dose of ibuprofen, an analgesic dose of ibuprofen, and acetaminophen in the treatment of patients with osteoarthritis of the knee. N Engl J Med 1991; 325: 87-91.
4. WOLFE F, ZHAO S, LANE N. Preference for nonsteroidal antiinflammatory drugs over acetaminophen by rheumatic disease patients: a survey of 1,799 patients with osteoarthritis, rheumatoid arthritis, and fibromyalgia. Arthritis Rheum 2000; 43: 378-385.
5. PINCUS T, CALLAHAN LF, WOLFE F, CUMMINS P, WEAVER A, CALDWELL J, et al. Arthrotec compared to acetaminophen: a clinical trial in patients with osteoarthritis of the hip or knee [abstract]. Arthritis Rheum 1999; 42(Suppl 9): S404.
6. ZHANG W, JONES A, DOHERTY M. Does paracetamol (acetaminophen) reduce the pain of osteoarthritis? A meta-analysis of randomised controlled trials. Ann Rheum Dis 2004; 63: 901-907.
7. STRAUBE S, TRAMÈR MR, MOORE RA, DERRY S, MCQUAY HJ. Mortality with upper gastrointestinal bleeding and perforation: effects of time and NSAID use. BMC Gastroenterol 2009; 9: 41.
8. GRIFFIN MR, YARED A, RAY WA. Non steroidal anti-inflammatory drugs and acute renal failure in elderly persons. Am J Epidemiol 2000; 151: 488-496.
9. PAGE J, HENRY D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients: an underrecognized public health problem. Arch Intern Med 2000; 160: 777-784.
10. TOWHEED T, SHEA B, WELLS G, HOCHBERG M. Analgesia and non-aspirin, non steroidal anti-inflammatory drugs for osteoarthritis of the hip (Cochrane review). In: The Cochrane library, issue 1. Oxford: Update Software, 2000. Accessed April 11, 2000.
11. MOORE RA, PHILIPS CJ. Cost of NSAID adverse effects to the UK National Health Service. J Med Econ 1999; 2: 45-55.
12. FRIES JF. NSAID gastropathy: the second most deadly rheumatic disease. Epidemiology and risk appraisal. J Rheumatol 1991; 28(suppl 3): 6-10.
13. ZHANG W, MOSKOWITZ RW, NUKI G, ABRAMSON S, ALTMAN RD, ARDEN N, BIERMA-ZEINSTRA S, BRANDT KD, CROFT P, DOHERTY M, DOUGADOS M, HOCHBERG M, HUNTER DJ, KWOH K, LOHMANDER LS, TUGWELL P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008; 16: 137-162.
14. JONES A, REGAN M, LEDINGHAM J, PATTRICK M, MANHIRE A, DOHERTY M. Importance of placement of intra-articular steroid injections. Br Med J 1993; 307: 1329-1330.
15. BRAGANTINI A, MOLINAROLI F. A pilot clinical evaluation of he treatment of hip osteoarthritis with hyaluronic acid. Curr Ther Res Lin Exp 1994; 55: 319-330.
16. QVISTGAARD E, KRISTOFFERSEN H, TERSLEV L, DANNESKIOLD-SAMSØE B, TORP-PEDERSEN S, BLIDDAL H. Guidance by ultrasound of intra-articular injections in the knee and hip joints. Osteoarthritis Cartilage 2001; 9: 512-517.
17. MIGLIORE A, MARTIN MARTIN LS, ALIMONTI A, VALENTE C, TORMENTA S. Efficacy and safety of viscosupplementation by ultrasound-guided intra-articular injection in osteoarthritis of the hip. Osteoarthritis Cartilage 2003; 11: 305-306.
18. ALTMAN R, ALARCÓN G, APPELROUTH D, BLOCH D, BORENSTEIN D, BRANDT K, BROWN C, COOKE TD, DANIEL W, FELDMAN D, et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hip. Arthritis Rheum 1991; 34: 505-514.
19. KELLGREN JH, LAWRENCE JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis 1957; 16(4): 494-502.
20. BLACK N. Why we need observational studies to evaluate the effectiveness of health care. Br Med J 1996; 312(7040): 1215-1218.
21. MIGLIORE A, TORMENTA S, MARTIN MARTIN LS, IANNESSI F, MASSAFRA U, CARLONI E, MONNO D, ALIMONTI A, GRANATA M. The symptomatic effects of intra-articular administration of hylan G-F 20 on osteoarthritis of the hip: clinical data of 6 months follow-up. Clin Rheumatol 2006; 25: 389-393.
22. MIGLIORE A, BIZZI E, UMASSAFRA U, ALIMONTI A, MARTIN MARTIN S, TORMENTA S. 18 months followup after intra-articular administration of hyalubrix® in 344 patients with symptomatic osteoarthritis of the hip. Osteoarthritis Cartilage 2008; 16: S118-S119.
23. MIGLIORE A, TORMENTA S, MASSAFRA U, BIZZI E, IANNESSI F, ALIMONTI A, GRANATA M. Intra-articular administration of hylan G-F 20 in patients with symptomatic hip osteoarthritis: tolerability and effectiveness in a large cohort study in clinical practice. Curr Med Res Opin 2008; 24: 1309-1316.
24. WADDELL DD. Viscosupplementation with hyaluronans for osteoarthritis of the knee: clinical efficacy and economic implications. Drugs Aging 2007; 24: 629-642.
25. GISLASON GH, RASMUSSEN JN, ABILDSTROM SZ, SCHRAMM TK, HANSEN ML, FOSBØL EL, SØRENSEN R, FOLKE F, BUCH P, GADSBØLL N, RASMUSSEN S, POULSEN HE, KØBER L, MADSEN M, TORP-PEDERSEN C. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med 2009; 169: 141-149.
26. WOBING M, DICKUT A, MAIER R, VETTER G. Viscosupplementation with hylan G-F 20: A six-month controlled trial of efficacy and safety in the osteoarthritic knee. Int J Drug Ther 1998; 20: 410-423.
27. DICKSON DJ, HOSIE G, ENGLISH JR, et al. A double-blind, placebo-controlled comparison of hylan G-F 20 against diclofenac in knee osteoarthritis. J Clin Res 2001; 4: 41-52.
28. LUSSIER A, CIVIDINO AA, MCFARLANE CA, OLSZYNSKI WP, POTASHNER WJ, DE MÉDICIS R. Viscosupplementation with hylan for the treatment of osteoarthritis: findings from clinical practice in Canada. J Rheumatol 1996; 23: 1579-1585.
29. BLOWER AL, BROOKS A, FENN GC, HILL A, PEARCE MY, MORANT S, BARDHAN KD. Emergency admission for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997; 11: 283-291
30. HENRY D. Non-steroidal anti-inflammatory drugs and the risk of development of congestive cardiac failure and functional renal impairment. Proceedings of the international conference on inflammopharmacology, San Francisco, 1997.
31. RICHARDSON CG, CHALMERS A, LLEWELLYN-THOMAS HA, KLINKHOFF A, CARSWELL A, KOPEC JA. Pain relief in osteoarthritis: patients' willingness to risk medication-induced gastrointestinal, cardiovascular, and cerebrovascular complications. J Rheumatol 2007; 34: 1569-1575.
32. TORRANCE GW, RAYNAULD JP, WALKER V, GOLDSMITH CH, BELLAMY N, BAND PA, SCHULTZ M, TUGWELL P. A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 2 of 2): economic results. Osteoarthritis Cartilage 2002; 10(7): 518-527.